8-K: Conduit Pharmaceuticals Forges Strategic Animal Health Partnership with Manoira, Expanding Glucokinase Activator Pipeline

Conduit Pharmaceuticals Inc. has entered into a joint development agreement with Manoira Corporation, an entity controlled by Conduit's CEO, to evaluate its pharmaceutical compounds AZD1656 and AZD5658 for animal health applications, funded by Manoira in exchange for 154,799 shares of Conduit common stock.

Summary

• Conduit Pharmaceuticals Inc. (Conduit) has signed a Joint Development Agreement with Manoira Corporation (Manoira) for an initial term of one year, with automatic renewals.
• Manoira, an entity controlled by Conduit's CEO, Dr. Andrew Regan, will evaluate Conduit's pharmaceutical compounds AZD1656 and AZD5658 (the Conduit Assets) for animal health indications.
• The collaboration aims to generate preclinical data to inform Conduit's human clinical programs and explore veterinary market opportunities, including potential combination therapies with Manoira's CBDA Cocrystal.
• Conduit granted Manoira a non-exclusive, non-transferable, non-sublicensable, fully paid-up, royalty-free license to the Conduit Assets for these Development Activities, but not for distribution, marketing, promotion, or sale.
• In exchange for Manoira's services and funding of all development costs, Conduit issued 154,799 shares of its common stock to Manoira, valued at approximately $500,000 based on the June 3, 2025 closing price of $3.23 per share.
• Conduit retains 100% ownership of all data and intellectual property generated relating to AZD1656 and AZD5658 for human applications.
• Joint intellectual property will be owned by both parties for Combination Therapies, with Conduit having exclusive ownership for human applications and Manoira for veterinary applications.
• A Joint Steering Committee (JSC) will be established with two members from each party to oversee and coordinate Development Activities and commercialization of Combination Therapies, requiring unanimous decisions.
• Conduit has committed to filing a Form S-3 registration statement for the resale of the issued shares within 60 days of issuance and to use commercially reasonable efforts to ensure its effectiveness within 60 days of filing.

Sentiment

Score: 7

Explanation: The sentiment is generally positive due to the strategic benefits of the collaboration, including cost-efficient data generation, expansion into a growing market, and retention of core IP. However, the related-party nature of the transaction and the minor dilution from share issuance temper the overall score slightly.

Positives

• The agreement provides Conduit with cost-efficient preclinical data, as Manoira will bear all development costs, potentially reducing Conduit's R&D expenses and accelerating human clinical trials.
• The collaboration offers cross-species insights that can enhance the probability of success for AZD1656 in human indications, strengthening Conduit's competitive edge.
• It opens a strategic entry into the estimated $15 billion animal health market, projected to grow at a CAGR of 6.5% through 2027, creating potential new revenue streams.
• Conduit retains full ownership of all intellectual property and data generated relating to AZD1656 and AZD5658 for human applications, maximizing shareholder value in its core therapeutic pipeline.
• The partnership leverages Manoira's specialized reformulation expertise, potentially leading to synergistic combination therapies that could redefine treatment standards in both veterinary and human applications.

Negatives

• The issuance of 154,799 shares of common stock to Manoira results in a slight dilution for existing Conduit shareholders.
• The agreement is a related-party transaction, as Manoira Corporation is controlled by Dr. Andrew Regan, who is also Conduit's Chief Executive Officer and a director, which may raise corporate governance concerns regarding potential conflicts of interest.
• Manoira receives a non-exclusive, fully paid-up, royalty-free license to Conduit's assets for animal health applications, meaning Conduit will not receive direct royalties from Manoira's use in this field.

Risks

• The inability to maintain the listing of Conduit's securities on Nasdaq.
• The ability to recognize the anticipated benefits of the business combination completed in September 2023 may be affected by competition.
• The ability of the combined company to grow and manage growth economically and hire and retain key employees.
• Risks that Conduit's product candidates in development fail clinical trials or are not approved by the U.S. Food and Drug Administration or other applicable authorities on a timely basis or at all.
• Changes in applicable laws or regulations.
• The possibility that Conduit may be adversely affected by other economic, business, and/or competitive factors.
• Disputes within the Joint Steering Committee (JSC) if unanimous consensus cannot be reached, potentially hindering development activities.

Future Outlook

Conduit Pharmaceuticals aims to accelerate its understanding of AZD1656's mechanism of action, safety profile, and potential efficacy across species, while retaining full ownership of intellectual property for human applications. The collaboration is expected to generate critical data to drive human clinical programs and open potential new revenue streams in the high-growth veterinary market, positioning Conduit as a cross-species leader in innovative, cost-efficient drug development.

Management Comments

• Dr. Freda Lewis-Hall, Chair of Conduit Pharmaceuticals, stated: "This transformative agreement with Manoira exemplifies our strategy of creating value through innovative collaborations. By leveraging Manoiras reformulation expertise in animal health, we are accelerating AZD1656s development, unlocking new commercial opportunities, and generating critical data to drive our human clinical programs all while maintaining full control of our intellectual property relating to AZD1656 and AZD5658. The inclusion of AZD5658 further demonstrates our intention to explore cross-species value through targeted, capital-efficient programs. Together, these efforts position Conduit as a cross-species leader in innovative, cost-efficient drug development."

Industry Context

The agreement positions Conduit to capitalize on the growing animal health market, estimated at $15 billion and projected to grow at a 6.5% CAGR through 2027, driven by rising pet ownership and demand for advanced veterinary therapies. By evaluating glucokinase activators like AZD1656 and AZD5658 in animal models, Conduit can gain cross-species insights that are valuable for both human and veterinary applications, a strategy that aligns with broader trends of leveraging translational research across species in drug development.

Comparison to Industry Standards

• The document does not provide specific comparable companies, projects, or results to assess the agreement in the context of global benchmarks. However, the strategy of leveraging animal health studies to inform human clinical programs is a recognized approach in pharmaceutical development for cost-efficiency and de-risking, particularly for compounds with potential cross-species efficacy like glucokinase activators in osteoarthritis.

Corporate Governance

Related Party Transactions

• Conduit Pharmaceuticals Inc. entered into a Joint Development Agreement with Manoira Corporation, an entity controlled by Dr. Andrew Regan, who is a director and the Chief Executive Officer of Conduit.
• As consideration for the agreement, Conduit issued 154,799 shares of its common stock, valued at approximately $500,000, to Manoira.

Stakeholder Impact

• Shareholders: Potential for long-term value creation through pipeline enhancement and new market entry, but also minor dilution from share issuance and potential concerns regarding the related-party nature of the transaction.
• Employees: No direct impact mentioned, but successful development could lead to future growth opportunities.
• Customers (future): Potential for new veterinary products and improved human therapies based on cross-species insights.
• Manoira Corporation: Receives a significant equity stake in Conduit and a royalty-free license to Conduit's assets for animal health, while bearing all development costs.
• Regulatory Authorities: The related-party transaction and unregistered share issuance will be subject to SEC scrutiny, requiring Conduit to file a registration statement for resale.

Next Steps

• Manoira will conduct Development Activities, including evaluating AZD1656 in animal osteoarthritis and exploring combination therapies.
• Conduit will use commercially reasonable efforts to prepare and file a Form S-3 registration statement for the resale of the 154,799 shares within 60 days after June 3, 2025.
• Conduit will use commercially reasonable efforts to ensure the Form S-3 registration statement becomes effective within 60 days after filing.
• The Joint Steering Committee (JSC) will be established within 30 days of the effective date to oversee and coordinate Development Activities and commercialization efforts, meeting at least quarterly.

Key Dates

Recommendation

Keywords

Conduit Pharmaceuticals, Manoira Corporation, Joint Development Agreement, AZD1656, AZD5658, Glucokinase Activators, Animal Health, Veterinary Medicine, Pharmaceutical Development, Preclinical Data, Human Clinical Programs, Intellectual Property, Related Party Transaction, Form 8-K, Biotechnology, Drug Development, Osteoarthritis, CBDA Cocrystal